Tech Company Financing Transactions
Avrobio Funding Round
Atlas Venture participated in a Seed funding round for Avrobio. The financing round closed on 2/22/2016.
Transaction Overview
Company Name
Announced On
2/22/2016
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Proceeds Purpose
The company will use the funds to accelerate development of two novel cell and gene therapies pioneered within the labs of Dr. Christopher Paige and Dr. Jeffrey Medin (now at the Medical College of Wisconsin) at the University Health Network (UHN) in Toronto, ON. Phase 1 programs will be in the clinic by early to mid-2016 in both acute myeloid leukemia (AML) and Fabry disease. The company will simultaneously work to expand its proprietary cell and gene therapy platform to treat additional indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 300 201
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
AVROBIO is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating AVROBIO is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geoff MacKay
Chief Scientific Officer
Chris Mason
Vice President
Kathryn McNaughton
VP - Bus. Development
Deanna Petersen
VP - Operations
Kim Warren
Browse more venture capital transactions:
Prev: 2/22/2016: SMASHsolar venture capital transaction
Next: 2/22/2016: Qubit venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs